TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

Vijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, Michael Timm, Linda Wellik, Timothy Halling, Animesh Pardanani, Ayalew Tefferi, Sundararasan Vincent Rajkumar, Shaji Kumar

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells'. Together they form a unique fingerprint.

Medicine & Life Sciences